Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent CIPN Grade-II, to Reduce Symptoms and to Improve the Quality of Life of Patients With CIPN

Chemotherapy-induced Polyneuropathy Clinical Trial

Official title:

Clinical Trial With Aconite Pain Oil in Oncology Patients Under Chemotherapy to Prevent Grade-II Chemotherapy-induced Polyneuropathy (CIPN), to Reduce Symptoms Typical of CIPN, and to Improve the Quality of Life of Patients With CIPN

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06186479
• Other study ID #: kp-acs-2
• Status: Recruiting
• Phase: Phase 3
• Start date: March 13, 2024
• Est. completion date: July 1, 2027

Study information

• Verified date: March 2024
• Source: WALA Heilmittel GmbH
• Contact: Florian Stintzing, Prof. Dr.
• Email: klin-pruef-klifo[@]wala.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The clinical trial is planned as a prospective, multicentre, blinded, randomised, placebo-controlled, national clinical trial in Germany. The clinical trial is designed for testing the prophylactic and therapeutic effects of Aconite pain oil as compared to placebo in oncological patients receiving neurotoxic chemotherapy with taxanes and/or platinum derivatives.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: July 1, 2027
• Est. primary completion date: July 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. A consent form, fully dated and signed by the patient and the principal investigator/investigator, is available

2. Patients with a minimum age of 18 years

3. Patients with a Karnofsky Index = 70%

4. Patients with an assumed life expectancy of at least 12 months

5. Patients with solid tumours

6. Patients who are scheduled to receive unmodified chemotherapy with taxanes or platinum derivatives or their combination approved in Germany for at least 3 months (start of chemotherapy within the next 10 days)

7. Patients of childbearing age must provide a negative pregnancy test

Exclusion Criteria:

1. Participation in an interventional trial (with an investigational product) that is concurrent or occurred within 4 weeks prior to inclusion in this trial

2. Pregnant and breastfeeding patients or patients who are not using effective contraception (Pearl index < 1)

3. Patients treated with topical and/or internally administered medicinal products or cosmetics containing aconite (Aconitum napellus), camphor (Camphora), lavender essential oil (Lavandulae aetheroleum), and/or quartz within 4 weeks prior to inclusion in this trial

4. Patients with known hypersensitivity to camphor and/or any of the other ingredients of Aconite Pain Oil, as well as peanut or soy

5. Patients who are not expected to be able to comprehend the significance of the clinical trial, to demonstrate the necessary compliance, and/or to complete the patient questionnaire and patient diary in the German-language for language-related, cognitive, or other reasons

6. Patients with a planned application of chemotherapy at =4-week intervals

7. Patients with alcohol/drug/medication dependency

8. Patients with known genetic predispositions to polyneuropathies

9. Patients with previous or current polyneuropathy irrespective of cause

10. Patients with previous or current use of neurotoxic medication (e.g., taxanes, platinum derivatives, metronidazole, isoniazid, amiodarone, vinca alkaloids, checkpoint inhibitors)

11. Patients with the following known comorbidities that predispose them to CIPN:

inadequately substituted hypothyroidism, renal insufficiency grade 4 and above, vasculitis/collagenosis, inadequately treated diabetes mellitus

12. Patients with active and/or clinically relevant infectious diseases: HIV, Lyme disease, hepatitis B/C, herpes infections

13. Known presence of multiple myeloma or non-Hodgkin's lymphoma

14. Present neurological diseases, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and other neurological diseases that make it difficult or impossible to assess the primary endpoint according to the investigator's opinion

15. Patients with metastases in the central nervous system

16. History of amputation of extremities

17. Patients with distal muscle weakness and/or atrophy

18. Skin lesions or other findings in the area of the extremities that make it impossible to use the investigational product (e.g., hand-foot syndrome)

19. Presence of any other serious acute or chronic organic or mental illness with severe impairment of the general condition that impairs or prevents regular participation in the trial

20. Use of co-analgesics such as gabapentin, pregabalin, amitriptyline, nortriptyline, clomipramine, imipramine, duloxetine 1 week before commencement of the trial (baseline) and intake during the trial before reaching CIPN grade III

21. Planned acupuncture for the treatment of CIPN during the trial

22. Topical application of substances such as lidocaine, capsaicin, botulinum toxin, amitriptyline, menthol to hands and/or feet up to 1 week before trial entry (baseline) and application during the trial

23. Electrotherapy on the extremities up to 1 week before the start of the trial (baseline) and during the trial

Related Conditions & MeSH terms

• Chemotherapy-induced Polyneuropathy
• Polyneuropathies

Intervention

Drug:
• Aconite pain oil
Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
• Placebo
Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.

Locations

Country	Name	City	State
Germany	Medizinische Fakultät Mannheim der Uniklinik Heidelberg	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
WALA Heilmittel GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of CIPN grade II and higher measured by "Common Terminology Criteria for Adverse Events" (CTC-AE v4.0 of 2010)	for neuralgia, paraesthesia, peripheral motor polyneuropathy, peripheral sensory polyneuropathy	on average every 3 weeks for max. 27 weeks
Primary	The date of occurrence of CIPN by the principal investigator/investigator using the EORTC-QLQ-CIPN20		on average every 3 weeks for max. 27 weeks